← All stocks

Ultragenyx Pharmaceutical Inc.

RARE Net selling
CIK 0001515673 #1874 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$19.66K
$17.41K on a plan · $0.00 straight out of an exercise
Sold at will
$2.25K
1 of 2 sales
Net
−$19.66K
−$2.25K against sales at will

By person

16 insiders · 2 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Huizenga Theodore Alan
SVP, Chief Accounting Officer
$19.66K (2) scheduled
−$19.66K
67,863
0.0688%
$920.90K
+56.2%
KAKKIS EMIL D
President & CEO
2,894,724
2.94%
$39.28M
+3.8%
Kassberg Thomas Richard
CBO & EVP
264,730
0.2685%
$3.59M
+4.7%
Huang Dennis Karl
See Remarks
147,845
0.1500%
$2.01M
+78.1%
Pinion John Richard
See Remarks
133,142
0.1350%
$1.81M
+47.2%
Harris Erik
EVP & Chief Commercial Officer
118,410
0.1201%
$1.61M
+73.5%
Crombez Eric
EVP and Chief Medical Officer
111,189
0.1128%
$1.51M
+121.6%
Horn Howard
Chief Financial Officer
96,295
0.0977%
$1.31M
−3.5%
Parschauer Karah Herdman
EVP and Chief Legal Officer
92,562
0.0939%
$1.26M
+56.0%
WELCH DANIEL G
Director
40,441
0.0410%
$548.78K
+50.1%
NARACHI MICHAEL
Director
40,441
0.0410%
$548.78K
+50.1%
Dunsire Deborah
Director
38,566
0.0391%
$523.34K
+53.8%
Fust Matthew K
Director
33,696
0.0342%
$457.25K
+66.8%
Ray Amrit
Director
31,116
0.0316%
$422.24K
+76.5%
SULIMAN SHEHNAAZ
Director
27,951
0.0284%
$379.30K
+38.4%
Sanders Corazon (Corsee) D.
Director
21,095
0.0214%
$286.26K
+75.7%

Nothing of that kind in this period.

What was left out

Form 4 filings counted 2
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 1
Sales straight out of an exercise 0
Sales at will 1
Transactions with no price 0
Shares from compensation/vesting 0
History held since 18 Oct 2016